Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: March 5th, 2012 - March 5th, 2013

Target Audience
This activity was developed for physicians, pharmacists, and other healthcare professionals practicing in a managed care environment.

Learning Objectives
Upon completion of this activity, the participant will be able to:

  • Explain the impact of key data presented at ASH 2011 on payers and providers in the treatment and management of multiple myeloma (MM)
  • Identify patient-/disease-associated factors, as well as economic factors that may impact the choice of therapeutic agent to formulate a management strategy using a risk-adapted approach to the treatment of MM
  • Appraise the evidence-based rationale for employing various novel agents and combinations of agents in appropriate sequence to optimize  therapeutic decisions for patients throughout the life cycle of MM
  • Examine long-term cost implications of MM therapy for both the patient and the healthcare system to make the best value-based treatment decisions for patients with MM

Physician Credit Designation
The Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical Learning Institute, Inc., and the Center of Excellence Media, LLC. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.5 contact hours (0.15 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-12-003-H01-P.

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Planners’ and Managers’ Disclosures

  • William J. Wong, MD, MLI Reviewer, has nothing to disclose.
  • Patricia A. Ensor, RPh, MBA, MLI Reviewer, has stock ownership in BioDelivery Sciences International and Human Genome Sciences.

Linda M. Ritter, PhD, Medical and Scientific Director, has nothing to disclose.

Faculty Disclosures 
Jonathan L. Kaufman, MD
, is Consultant to Celgene, Millennium, Novartis, and Onyx.

James T. Kenney, Jr, RPh, MBA, has nothing to disclose.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for any agent discussed in this program should be inferred.

Estimated time to complete activity: 1.5 hours

Related Items
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost Effective Management of Multiple Myeloma
Jonathan L. Kaufman, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
The Evolving Role of Outcomes and End Points in Evaluating Therapy for Hematologic Malignancies: Value-Driven Benefit Design and Utilization Management Strategies
Gary C. Yee, PharmD, FCCP, BCOP, James T. Kenney Jr, RPh, MBA, Michael Mauro, MD
Supplements published on July 15, 2011
Considerations in Multiple Myeloma Ask the Experts: Newly Diagnosed Patients
Jonathan L. Kaufman, MD , Charise Gleason, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Supplements published on March 31, 2011
ASH 2010 Update on Multiple Myeloma: Treatment Trends and Strategies for Value-Based Care
John Fox, MD, James T. Kenney Jr, RPh, MBA
Supplements published on March 4, 2011
ASH 2010 Update on Non-Hodgkin Lymphoma: Alignment of the Current Treatment Landscape and Value-Based Care
John Fox, MD, James T. Kenney Jr, RPh, MBA
Supplements published on February 28, 2011
Challenging Cases in Multiple Myeloma: A Dialogue Between Community and Academic Clinicians to Improve Patient Care and Outcomes
Leon Dragon, MD, FACP, Hakan Kaya, MD, Jonathan L. Kaufman, MD , Shoba Kankipati, MD , Noopur Raje, MD, Ari Umutyan, MD
Supplements published on December 3, 2010
The 32nd Annual San Antonio Breast Cancer Symposium Highlights: A Payer's and Pharmacist's Perspective
James T. Kenney Jr, RPh, MBA
Supplements published on February 15, 2010
Last modified: March 21, 2014